What Will Happen to IntelliPharmaCeutics International Inc. Next? The Stock Just Declined A Lot

 What Will Happen to IntelliPharmaCeutics International Inc. Next? The Stock Just Declined A Lot

The stock of IntelliPharmaCeutics International Inc. (TSE:I) is a huge mover today! About 30,775 shares traded hands or 11.71% up from the average. IntelliPharmaCeutics International Inc. (TSE:I) has risen 52.73% since April 22, 2016 and is uptrending. It has outperformed by 46.71% the S&P500.
The move comes after 5 months negative chart setup for the $124.59M company. It was reported on Nov, 28 by Barchart.com. We have $3.81 PT which if reached, will make TSE:I worth $8.72 million less.

Another recent and important IntelliPharmaCeutics International Inc. (TSE:I) news was published by Seekingalpha.com which published an article titled: “IntelliPharmaCeutics International Has Huge Upside With Limited Downside” on November 10, 2016.

IntelliPharmaCeutics International Inc is a Canada pharmaceutical firm specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The company has a market cap of $124.59 million. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. It currently has negative earnings. It has developed several drug delivery systems and a pipeline of products and product candidates in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.

I.TO Company Profile

Intellipharmaceutics International Inc., incorporated on October 22, 2009, is a pharmaceutical firm specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, the Company has developed several drug delivery systems and a pipeline of products and product candidates at various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix family of technologies includes IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle, Point of Divergence Drug Delivery System (nPODDDS) and Paradoxical OverDose Resistance Activating System (PODRAS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment